Revolution Medicines investor relations material

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The Company's portfolio includes programs that target shared signaling mutations involving RAS and EGFR pathways. Through its technology platform of small molecules that enter cells through multiple mechanisms of action, Revolution Medicines aims to significantly increase drug concentrations at key adverse driver points required for cell growth and survival.